Literature DB >> 31631693

Serum Levels of Coll2-1, a Specific Biomarker of Cartilage Degradation, Are Not Affected by Sampling Conditions, Circadian Rhythm, and Seasonality.

Anne-Christine Hick1, Misch Fonck1, Bérénice Costes1, Elisabeth Cobraiville1, Sébastien Pirson1, Laetitia Garcia1, Alain Labasse1, Steven Vander Poelen1, Yves Henrotin1,2.   

Abstract

OBJECTIVE: To assess intraindividual biological variability of serum cartilage specific biomarker Coll2-1 and define the best standardized conditions for blood sampling.
DESIGN: Blood samples were taken from 116 subjects with knee osteoarthritis (OA) at a single time point (PRODIGE study) and from 15 healthy subjects under various conditions, including fasting condition, sampling time and season, blood treatment, and type of blood collection tube (COVAR study). Type II collagen-specific biomarker Coll2-1 was directly measured in serum using an immunoassay.
RESULTS: There was no significant difference on Coll2-1 values between samples collected at any of the 5 sampling times or at any of the sampling days measured. None of the sampling parameters tested had a significant impact on Coll2-1 value (clotting time, clotting temperature and temperature of blood centrifugation, type of tube). On the contrary, differences were found in between subjects and between subjects with knee OA and healthy subjects.
CONCLUSION: Coll2-1 measurement is not affected by sampling specific conditions, circadian rhythm or seasons but was found elevated in subject with knee OA indicating that Coll2-1 serum variation is not linked to the study environment, but to cartilage degradation in OA. Coll2-1 assay is sufficiently robust for use in OA clinical trials.

Entities:  

Keywords:  biomarkers; cartilage; clinical study; knee; osteoarthritis

Mesh:

Substances:

Year:  2019        PMID: 31631693      PMCID: PMC8808846          DOI: 10.1177/1947603519878489

Source DB:  PubMed          Journal:  Cartilage        ISSN: 1947-6035            Impact factor:   3.117


  25 in total

1.  One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression.

Authors:  M A Deberg; A H Labasse; J Collette; L Seidel; J-Y Reginster; Y E Henrotin
Journal:  Osteoarthritis Cartilage       Date:  2005-09-09       Impact factor: 6.576

2.  Decrease of serum biomarker of type II Collagen degradation (Coll2-1) by intra-articular injection of an autologous plasma-rich-platelet in patients with unilateral primary knee osteoarthritis.

Authors:  Rasha Mohamed Fawzy; Nashwa Ismail Hashaad; Amira Ibrahim Mansour
Journal:  Eur J Rheumatol       Date:  2017-06-01

Review 3.  Classification of osteoarthritis biomarkers: a proposed approach.

Authors:  D C Bauer; D J Hunter; S B Abramson; M Attur; M Corr; D Felson; D Heinegård; J M Jordan; T B Kepler; N E Lane; T Saxne; B Tyree; V B Kraus
Journal:  Osteoarthritis Cartilage       Date:  2006-06-02       Impact factor: 6.576

4.  Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO₂ ) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study.

Authors:  Y Henrotin; X Chevalier; M Deberg; J C Balblanc; P Richette; D Mulleman; B Maillet; F Rannou; C Piroth; P Mathieu; T Conrozier
Journal:  J Orthop Res       Date:  2013-02-19       Impact factor: 3.494

Review 5.  Biomarkers as drug development tools: discovery, validation, qualification and use.

Authors:  Virginia B Kraus
Journal:  Nat Rev Rheumatol       Date:  2018-06       Impact factor: 20.543

Review 6.  OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.

Authors:  V B Kraus; F J Blanco; M Englund; Y Henrotin; L S Lohmander; E Losina; P Önnerfjord; S Persiani
Journal:  Osteoarthritis Cartilage       Date:  2015-05       Impact factor: 6.576

7.  Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.

Authors:  V B Kraus; B Burnett; J Coindreau; S Cottrell; D Eyre; M Gendreau; J Gardiner; P Garnero; J Hardin; Y Henrotin; D Heinegård; A Ko; L S Lohmander; G Matthews; J Menetski; R Moskowitz; S Persiani; A R Poole; J-C Rousseau; M Todman
Journal:  Osteoarthritis Cartilage       Date:  2011-03-23       Impact factor: 6.576

8.  Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project.

Authors:  Joanne M Jordan; Gheorghe Luta; Thomas Stabler; Jordan B Renner; Anca D Dragomir; Vladimir Vilim; Marc C Hochberg; Charles G Helmick; Virginia B Kraus
Journal:  Arthritis Rheum       Date:  2003-03

9.  Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index.

Authors:  U Mouritzen; S Christgau; H-J Lehmann; L B Tankó; C Christiansen
Journal:  Ann Rheum Dis       Date:  2003-04       Impact factor: 19.103

10.  Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial.

Authors:  Yves Henrotin; Myriam Gharbi; Yvan Dierckxsens; Fabian Priem; Marc Marty; Laurence Seidel; Adelin Albert; Elisabeth Heuse; Valérie Bonnet; Caroline Castermans
Journal:  BMC Complement Altern Med       Date:  2014-05-17       Impact factor: 3.659

View more
  1 in total

1.  Cartilage Biomarkers Coll2-1 and Coll2-1NO2 Are Associated with Knee OA MRI Features and Are Helpful in Identifying Patients at Risk of Disease Worsening.

Authors:  Anne-Christine Hick; Michel Malaise; Damien Loeuille; Thierry Conrozier; Yves Maugars; Franz Pelousse; Cédric Tits; Yves Henrotin
Journal:  Cartilage       Date:  2021-06-15       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.